CYTOKINETICS (CYTK) director receives share grant and 4,301-share option award

Rhea-AI Filing Summary

CYTOKINETICS INC director John T. Henderson reported new equity awards. He received a grant of 2,851 shares of common stock at no cost, bringing his direct holdings to 78,088 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.1500 per share, exercisable starting on June 27, 2026 and expiring on May 26, 2036. In addition, 83 shares are reported as indirectly owned through his spouse. These are compensation-related awards, not open-market purchases or sales.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider HENDERSON JOHN T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	--
Grant/Award	Common Stock	2,851	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct, null); Common Stock — 78,088 shares (Direct, null); Common Stock — 83 shares (Indirect, by Spouse)

Footnotes (1)

Key Figures

Share grant: 2,851 shares Option grant size: 4,301 shares Option exercise price: $77.1500 per share +4 more

7 metrics

Share grant 2,851 shares Common Stock grant to director on May 27, 2026

Option grant size 4,301 shares Non-qualified stock option covering common stock

Option exercise price $77.1500 per share Strike price for non-qualified stock option

Option exercisable date June 27, 2026 Earliest exercise date for the option

Option expiration May 26, 2036 Expiration date for the option grant

Direct common shares after award 78,088 shares Director’s direct CYTOKINETICS common stock holdings

Indirect spouse holdings 83 shares Common stock held indirectly by spouse

Key Terms

Non-Qualified Stock Option (Right to Buy), grant/award acquisition, indirect, transaction code A

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

indirect financial

"ownership_type: "indirect" with nature_of_ownership "by Spouse""

transaction code A financial

"transaction_code: "A" with description "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON JOHN T

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		2,851	A	$0	78,088	D
Common Stock								83	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Henderson	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did CYTK director John T. Henderson report?

John T. Henderson reported receiving 2,851 shares of CYTOKINETICS INC common stock and a non-qualified stock option for 4,301 shares. Both were recorded as grants or awards, meaning compensation-related acquisitions rather than open-market purchases or sales.

How many CYTK shares does John T. Henderson hold after these awards?

After the reported awards, John T. Henderson directly holds 78,088 shares of CYTOKINETICS INC common stock. The filing also shows 83 additional shares held indirectly through his spouse, giving investors a clearer picture of his total reported equity exposure.

What are the key terms of John T. Henderson’s new CYTK stock option?

He received a non-qualified stock option covering 4,301 shares of CYTOKINETICS INC common stock at an exercise price of $77.1500 per share. The option becomes exercisable on June 27, 2026 and expires on May 26, 2036, defining a long exercise window.

Were there any open-market buys or sells by John T. Henderson in this CYTK Form 4?

The Form 4 shows grant or award acquisitions and a holding entry, but no open-market purchases or sales. Transactions are coded as awards (code A) or holdings, indicating routine compensation and ownership reporting rather than discretionary market trading.

How is indirect ownership reported for CYTK shares held by John T. Henderson’s spouse?

The filing lists 83 CYTOKINETICS INC common shares as indirectly owned "by Spouse." This indicates the shares are held in a spouse’s account, and the position is reported as indirect ownership separate from Henderson’s 78,088 directly held shares.